用新的化学蛋白诱导有针对性的,独立于卡斯帕斯的亡,用于治疗固体癌症
Orly Melloul1, Samar Zabit1, Michal Lichtenstein1
1Department of Biochemistry and Molecular Biology, Faculty of Medicine, Institute for Medical Research Israel-Canada (IMRIC), The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.
Cancers
|April 14, 2025
概括
一种新型的GnRH-AIF化学蛋白有效地通过独立于酶的途径准和消除固体瘤,提供了一种有前途的新型癌症治疗方法. 这种方法克服了传统的亡疗法所见的耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物技术是生物技术.
背景情况:
- 传统的抗癌治疗通常依赖于酶依赖的亡,由于导致癌症耐药性的突变,这可能是无效的.
- 淋巴激素释放激素类似物 (GnRH) 准在各种固体瘤上过度表达的GnRH受体 (GnRH-R).
- 诱导亡因子 (AIF) 调解了独立于酶的细胞死亡,为传统的亡途径提供了替代方案.
研究的目的:
- 开发和评估一种新的化学蛋白,GnRH-AIF,用于向癌症治疗.
- 调查GnRH-AIF的作用机制,重点关注其酶独立的亡途径.
- 在固体癌症模型中评估GnRH-AIF的抗瘤疗效.
主要方法:
- 构建,表达和净化GnRH-AIF化学蛋白.
- 在体外评估GnRH-AIF进入并杀死过度表达GnRH-R的固体癌细胞系的能力.
- 使用人类结肠癌器官模型对GnRH-AIF抗瘤功效的实体评估.
主要成果:
- GnRH-AIF专门向并有效地杀死过度表达GnRH-R的固体癌细胞.
- 进入细胞后,GnRH-AIF转移到细胞核,诱导DNA碎片化和独立于酶的亡.
- 由GnRH-AIF诱导的细胞死亡依赖于ENDOG和PPIA蛋白质,这些蛋白质参与DNA降解组复合体的形成.
结论:
- GnRH-AIF 嵌合蛋白显示出作为一种新型治疗剂的显著潜力,用于过度表达 GnRH-R.R. 的固体瘤.
- 由GnRH-AIF利用的酶独立的亡途径提供了一种克服抗常规癌症治疗方法的策略.
- 对GnRH-AIF的进一步研究可能会导致耐火固体癌症的新治疗选择.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:31The Intrinsic Apoptotic Pathway
5.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.6K
01:27Tumor Immunotherapy
404
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
404